31 results about "Enhanced dissolution" patented technology

A method for preparing poorly water soluble drug particles is disclosed. The method comprises dissolving a drug in at least one organic solvent to form a drug/organic mixture, spraying the drug/organic mixture into an aqueous solution and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles. The resulting drug particles are in the nanometer to micrometer size range and show enhanced dissolution rates and reduced crystallinity when compared to the unprocessed drug. The present invention additionally contemplates products and processes for new drug formulations of insoluble drug particles having high dissolution rates and extremely high drug-to-excipient ratios.

The present invention discloses pharmaceutical-grade ferric organic compounds having enhanced dissolution rate. These ferric organic compounds, including but are not limited to ferric citrate, are useful for treating chronic kidney disease.

A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling. The blend is then compressed to form tablets that have an enhanced dissolution profile for the medicinally active ingredient.

The invention discloses a deflazacort oral preparation and a preparation method thereof. The deflazacort oral preparation comprises micronized deflazacort, wherein 50 to 100% of deflazacort particles have particle sizes less than or equal to 50 micrometers. The micronized deflazacort oral preparation is prepared from 2 to 40% of micronized deflazacort, 50 to 95% of one or more fillers, 1 to 10% of one or more disintegrants, 1 to 10% of one or more binders and 0.3 to 1% of a lubricant. The micronized deflazacort oral preparation is characterized in that through a process of mixing raw materials and lactose in an equal amount increasing way, a uniformity degree and a dissolution rate of raw materials can be improved; micronized deflazacort can improve a dissolution degree in vitro; and selected and combined raw materials are suitable for drug molding and have a high stability and good drug effects.

The present invention relates to a fenofibrate composition comprising: fenofibrate, a surfactant, a hydrophilic polymer and one or more anti-foaming agents. The invention also relates to a novel process for preparing said composition that has enhanced dissolution and absorption characteristics.

Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes.

The invention discloses an efficient scleroglucan extraction and purificatiodn method and an application thereof. The method includes: 1), performing microwave enhanced dissolution after dilute alkali dissolution by a mycelium contained scleroglucan crude product or a high-concentration scleroglucan fermentation liquid raw material; 2), performing separation on the scleroglucan solution obtained form the step 1) to remove the insoluble mycelium with frame filter or centrifugal separation and merging a scrubbing solution into the scleroglucan solution by adopting the mycelium obtained from the scrubbing solution; 3), neutralizing the scleroglucan solution after bacterial removal; 4), treating the scleroglucan solution through an ultrafiltration membrane prior to desalting and concentrating, and washing the scleroglucan concentrated solution is washed through water and prior to desalting; 5), precipitating and washing the scleroglucan with ethyl alcohol to obtain the product after drying. Through treatment of a series of physical methods, the stable and efficient scleroglucan preparation process is established, chemical reaction is not needed, impurity components in the finished product are reduced, and the purity of the targeted scleroglucan product is up to 90%.

A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having a relatively rapid dissolution rate in aqueous media. Also provided are novel solvated crystalline forms of eplerenone that, when desolvated, can yield Form H eplerenone. Also provided is amorphous eplerenone. Pharmaceutical compositions are provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.

Drug particles which are essentially crystalline and have a mean particle size below about 2 microns, when dispersed in water, are described. When added to an aqueous medium at 25-95% of the equilibrium solubility of the drug substance, the drug particles show complete dissolution, as characterized by a 95% reduction in turbidity, in less than 5 minutes. Using a controlled precipitation process to prepare such drug particles is also described. Such drug particles exhibit an enhanced dissolution rate and better stability as compared to particles prepared according to processes described in the prior art.

The present invention is in the field of detergent powders. The invention particularly relates to detergent granules exhibiting improved dissolution behaviour for faster release of active to a wash liquor. A detergent particle that provides further improved dissolution, even after storage, remains to be desired. This applies not only to detergent powder composition, but also to compositions in tablet form. It is an object of the present invention to provide a detergent composition having enhanced dissolution properties. Surprisingly it has been found that a granule comprising a mixture of a magnesium salt of linear alkylbenzene sulphonic acid (Mg(LAS)

A complexation process between a cyclodextrin and active pharmaceutical ingredients is disclosed, and comprises a process for preparing a complex of at least one cyclodextrin and at least one active pharmaceutical ingredient comprising the steps of

The described process has high throughput with higher yields of complexation in less time than prior art methods.

The complexes obtained by the invention are characterized by having enhanced dissolution and/or bioavailability of the active pharmaceutical ingredient in body fluids.

The objective of this invention is to develop a novel wafer and capsule formulations using fenofibrate which is difficult to dissolve and control its release rate in vitro.

A novel crystalline form (Form H) of the aldosterone receptor antagonist drug eplerenone is provided having relatively hich physical stability at normal temperatures of storage and use. Pharmaceutical compositions are also provided comprising Form H eplerenone, optionally accompanied by one or more other solid state forms of eplerenone, in a total unit dosage amount of eplerenone of about 10 to about 1000 mg, and further comprising one or more pharmaceutically acceptable excipients. Processes are provided for preparing Form H eplerenone and for preparing compositions comprising Form H eplerenone. A method for prophylaxis and/or treatment of an aldosterone-mediated condition or disorder is also provided, comprising administering to a subject a therapeutically effective amount of eplerenone, wherein at least a fraction of the eplerenone present is Form H eplerenone.